FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Wasiiiigton, D.C. 20049	OMB APPROVAL			
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP	OMB Number:	3235		

OMB Number:	3235-0287							
Estimated average burden								
hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Elsbree David B</u>						2. Issuer Name and Ticker or Trading Symbol T2 Biosystems, Inc. [TTOO]										ship of Reporting Pe applicable) irector		erson(s) to Issuer 10% Owner		
(Last)	(F RTWELL A	First)	(Middle)			3. Date of Earliest Transaction (Month/Day/Year) 01/01/2020									Officer (give title below)		Other (s below)		specify	
(Street)	TON M	1A	02421		4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)								Line)	Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City)	(5	State)	(Zip)																	
1. Title of Security (Instr. 3) 2. Trans Date				action				Code (Instr. 5)) or 5. Amount of			6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)			
									Code	v	Amount	(A) or (D)		Price	Transaction(s) (Instr. 3 and 4)				(111311. 4)	
Common	Common Stock			01/01/2020				M		13,28	89 A		(1)	96,397		D				
Common	Stock														10,			By spouse ⁽²⁾		
			Table II -						uired, D , option						Owned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deeme Execution if any (Month/Day	Date, 1	4. Transaction Code (Instr. 8)				6. Date Exercisa Expiration Date (Month/Day/Yea		•	7. Title and A of Securities Underlying Derivative Se (Instr. 3 and 4		urity	8. Price of Derivative Security (Instr. 5)	9. Numbe derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	e s ally g	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercisab		Expiration Date	Title	or Nu of	nount mber ares						
Restricted Stock Units	(1)	01/01/2020			A		34,188		(3)		(3)	Commo Stock	ⁿ 34	,188	\$0.00	34,18	8	D		
Restricted Stock	(1)	01/01/2020			M		13,289		(4)		(4)	Commo	n 13	,289	\$0.00	13,28	9	D		

Explanation of Responses:

- 1. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
- 2. The reporting person disclaims ownership of these securities and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or
- 3. The restricted stock units were granted in accordance with the Issuer's Non-Employee Director Compensation Plan and vest on January 1, 2021.
- 4. On January 1, 2019 the reporting person was granted 13,289 restricted stock units that vested on January 1, 2020.

Remarks:

/s/ John Sprague, Attorney-in-01/03/2020 **Fact**

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.